Methylene Blue and Malaria
Author Information
Author(s): Zoungrana Augustin, Coulibaly Boubacar, Sié Ali, Walter-Sack Ingeborg, Mockenhaupt Frank P., Kouyaté Bocar, Schirmer R. Heiner, Klose Christina, Mansmann Ulrich, Meissner Peter, Müller Olaf
Primary Institution: Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso
Hypothesis
The study aimed to assess the safety and efficacy of Methylene Blue combined with Artesunate or Amodiaquine for treating uncomplicated falciparum malaria.
Conclusion
Methylene Blue combined with Amodiaquine is a promising alternative treatment for malaria in Africa.
Supporting Evidence
- Methylene Blue combined with Artesunate showed a lower rate of adequate clinical and parasitological response compared to the standard treatment.
- No drug-related serious adverse events and no deaths occurred during the study.
- The study found significant differences in parasite clearance time among the treatment groups.
Takeaway
This study tested a new medicine for malaria in kids and found that one combination worked really well.
Methodology
An open-label randomized controlled phase II trial was conducted with 180 children aged 6–10 years with uncomplicated falciparum malaria.
Potential Biases
There may be bias due to the open-label design of the trial.
Limitations
The study was limited to a specific age group and location, which may affect the generalizability of the results.
Participant Demographics
Children aged 6-10 years with uncomplicated falciparum malaria.
Statistical Information
P-Value
p=0.004
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website